https://www.selleckchem.com/pr....oducts/crenolanib-cp
6%) (P = .16). However, the 3-year overall survival (OS) rate in the AML-05 study (62.9%, 95% CI 56.3-68.8%) was slightly lower than that in the AML99 study (71.6%, 95% CI 63.2-78.5%) (P = .06, mainly due to decreased remission induction rate and increased nonrelapsed mortality. In conclusion, reductions in the number of PRC courses from four to three, together with repetitive cycles of high-dose cytarabine, were acceptable for non-CBF childhood AML. Our aim was to study whether systemic metabolites are associated with ma
Like
Comment
Share
